Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:20:23.290Z.
Consensus retrieved: 2026-10-06T08:16:12.972Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:20:23.290Z.
Quote observation: 2026-10-06T14:20:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Forward PE Ratio (N/A) = Dated Quote Price ($4.99) / Consensus Forward EPS ($-3.15)
FORWARD PE RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.20M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.20M | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | N/A |
| BGM Group Ltd. (BGM)vs › | $112.03M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | N/A |
| Immunic, Inc. (IMUX)vs › | $106.73M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.17M | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.61M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.15 | $-3.80 – $-2.46 | 9 | n/m |
| 2027-12-31 | $-2.56 | $-3.62 – $-1.84 | 9 | n/m |
| 2028-12-31 | $-2.47 | $-4.13 – $-1.10 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
